EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, HeXun Biosciences Co's enterprise value is NT$2,960.2 Mil.
HeXun Biosciences Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$286.4 Mil. Therefore, HeXun Biosciences Co's EV-to-Revenue for today is 10.34.
The historical rank and industry rank for HeXun Biosciences Co's EV-to-Revenue or its related term are showing as below:
ROCO:6986'
s EV-to-Revenue Range Over the Past 10 Years
Min: 9.92 Med: 21.47 Max: 47.94
Current: 10.34
During the past 5 years, the highest EV-to-Revenue of HeXun Biosciences Co was 47.94. The lowest was 9.92. And the median was 21.47.
ROCO:6986's EV-to-Revenue is ranked worse than 56.47% of 997
companies
in the Biotechnology industry
Industry Median: 7.39
vs ROCO:6986: 10.34
HeXun Biosciences Co EV-to-Revenue Historical Data
The historical data trend for HeXun Biosciences Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of HeXun Biosciences Co's EV-to-Revenue
For the Biotechnology subindustry, HeXun Biosciences Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeXun Biosciences Co's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HeXun Biosciences Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where HeXun Biosciences Co's EV-to-Revenue falls into.
HeXun Biosciences Co's current Enterprise Value is NT$2,960.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. HeXun Biosciences Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$286.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co (ROCO:6986) EV-to-Revenue Explanation
HeXun Biosciences Co's share price for today is NT$71.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was NT$6.23.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeXun Biosciences Co EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of HeXun Biosciences Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6986 has been successfully added to your